Cromos Pharma, where the patients are

Merck

Trial results for AbbVie’s Hepatitis C candidate heat up race for effective treatment

Monday, April 14, 2014 12:51 PM

The race to replace interferon with a far more effective treatment for hepatitis C has become one of the most promising and lucrative battles in drug development, as AbbVie, Gilead Sciences, Merck and Bristol-Myers Squibb vie for the finish line.

More... »

CRF Health eCOA webinar series

TrialNetworks wins Disruptive Technology and Innovator of the Year Award

Friday, April 11, 2014 11:37 AM

TrialNetworks and its Clinical Trial Optimization System won the Disruptive Innovator and Technology of the Year award from Partnerships in Clinical Trials 2014. The award honors an individual or a company with a new disruptive technology platform that has increased the efficiency and quality of clinical trials. TrialNetworks technology is used by companies including Merck, Biogen Idec, Ariad Pharmaceuticals and Infinity Pharmaceuticals to optimize clinical operations from startup through closeout.

More... »


Merck, Ferring, WHO work to prevent post-partum hemorrhage

Monday, April 7, 2014 12:33 PM

Merck and Ferring Pharmaceuticals are collaborating with the World Health Organization (WHO) to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding (post-partum hemorrhage) in women after childbirth, which is designed to be stable at room temperature, even in hot and tropical climates (ICH climatic zone IV).

More... »

EMD Serono inks research agreement with Pfizer, Broad Institute

Wednesday, April 2, 2014 01:41 PM

EMD Serono, a subsidiary of Merck, has signed a research agreement with Pfizer and the Broad Institute in Cambridge, Mass. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients. The research project will be jointly funded by EMD Serono and Pfizer.

More... »

Annalisa Jenkins named IIR Partnerships’ Woman of the Year

Tuesday, April 1, 2014 01:43 PM

Annalisa Jenkins, former executive vice president, head of global R&D at Merck Serono, has been named IIR Partnerships’ Woman of the Year.

More... »

Antibacterial drugs market to top $45B globally in 2019

Monday, March 24, 2014 02:48 PM

According to a new market report from Transparency Market Research, a global market intelligence company, the global antibacterial drugs market was valued at $43.55 billion in 2012 and is expected to grow at a CAGR of 0.3% from 2013 to 2019, to reach an estimated value of $45.09 billion in 2019.

More... »

GHIT Fund awards $12M for neglected diseases, launches investment program

Thursday, March 20, 2014 02:22 PM

The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership bringing Japanese experience and investment to the global fight against infectious diseases, has announced three grants worth a total of $6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms.

More... »

Mytrus launches innovation advisory board

Wednesday, March 19, 2014 12:43 PM

Mytrus, a provider of electronic informed consent and e-clinical technologies, has created a new Innovation Advisory Board comprised of industry experts to help shape the future of its clinical products and services.

More... »

Merck’s investigational HIV therapy Doravirine demonstrates antiviral activity

Friday, March 7, 2014 10:01 AM

Merck has presented data from the dose-ranging portion of an ongoing phase IIb clinical trial of doravirine, the company’s investigational next-generation, non-nucleoside reverse transcriptase inhibitor (NNRTI). Interim data demonstrating potent antiretroviral (ARV) activity for four doses of once-daily, oral doravirine in combination with tenofovir/emtricitabine in treatment-naïve, HIV-1 infected adults after 24 weeks of treatment were presented during a late-breaker oral session. Based on these findings as well as other data from the doravirine clinical program, Merck plans to initiate a phase III clinical trial program for doravirine in combination with ARV therapy in the second half of 2014.

More... »

CEOi, NY Academy of Sciences to launch Global Alzheimer's Platform

Wednesday, February 26, 2014 01:21 PM

The Global CEO Initiative (CEOi) on Alzheimer's Disease and the New York Academy of Sciences have convened representatives from industry, academia, government and nonprofits to launch the development of a Global Alzheimer's Platform (GAP), designed to reduce the time and costs of Alzheimer's clinical trials, develop an infrastructure that promotes innovation and assure international collaboration.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs